Catatan sumber primer
PenentuHasil topline
ADCT: LOTIS-5 Fase 3 topline memenuhi titik akhir PFS untuk ZYNLONTA + rituximab
Uji coba Fase 3 LOTIS-5 memenuhi titik akhir PFS primer dengan signifikansi statistik (HR 0.73, p=0.008). ADC Therapeutics merencanakan pertemuan pra-sBLA dengan FDA pada Agustus 2026 dan pengajuan sBLA pada Q4 2026 untuk mencari persetujuan penuh ZYNLONTA plus rituximab pada r/r DLBCL.
Fakta utama
- Diajukan
- 3 Jun 2026, 20.17
- Peristiwa
- Hasil topline
- Arah
- Positif
- Perusahaan
ADCTADC Therapeutics- Sumber
- SEC 8-K
- Keyakinan
- Bersumber
- HR
- 0.73
- CR rate
- 39.5% vs 26.7%
- p-value
- 0.008
- median PFS
- 6.1 vs 4.7 months
- median docr
- 16.8 vs 12.3 months
Kutipan sumber
false 0001771910 0001771910 2026-06-03 2026-06-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 3, 2026 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Number) N/A (IRS Employer Identification Number) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of Principal Executive Offices) (Zip Code) + 41 21 653 02 00 (Registrant’s Telephone Number) N/A (Former Name or Former Address, if Changed Since Last Report) Ch